Ferroptosis Regulator Information
General Information of the Ferroptosis Regulator (ID: REG10335)
Full List of the Ferroptosis Target of This Regulator and Corresponding Disease/Drug Response(s)
GABARAPL1
can regulate the following target(s), and cause disease/drug response(s). You can browse detail information of target(s) or disease/drug response(s).
Browse Target
Browse Disease
Unspecific Target [Unspecific Target]
In total 1 item(s) under this target | ||||
Experiment 1 Reporting the Ferroptosis Target of This Regulator | [1] | |||
Responsed Disease | Hepatocellular carcinoma | ICD-11: 2C12 | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Ferroptosis | hsa04216 | |||
Cell Process | Cell ferroptosis | |||
Cell proliferation | ||||
In Vitro Model |
SNU-449 cells | Adult hepatocellular carcinoma | Homo sapiens | CVCL_0454 |
SK-HEP-1 cells | Liver and intrahepatic bile duct epithelial neoplasm | Homo sapiens | CVCL_0525 | |
MHCC97-H cells | Adult hepatocellular carcinoma | Homo sapiens | CVCL_4972 | |
SMMC-7721 cells | Endocervical adenocarcinoma | Homo sapiens | CVCL_0534 | |
LM3 cells | Malignant neoplasms | Mus musculus | CVCL_D269 | |
Huh-7 cells | Hepatocellular carcinoma | Homo sapiens | CVCL_0336 | |
PLC/PRF/5 cells | Hepatocellular carcinoma | Homo sapiens | CVCL_0485 | |
L-02 cells | Endocervical adenocarcinoma | Homo sapiens | CVCL_6926 | |
Response regulation | GABARAPL1 was downregulated in hepatocellular carcinoma (HCC) tumor-repopulating cells (TRC; a type of CSLC). Its downregulation decreased the sensitivity of HCC TRC to erastin- or sorafenib-triggered ferroptosis. | |||
Hepatocellular carcinoma [ICD-11: 2C12]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response | [1] | |||
Target Regulator | Gamma-aminobutyric acid receptor-associated protein-like 1 (GABARAPL1) | Protein coding | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Ferroptosis | hsa04216 | |||
Cell Process | Cell ferroptosis | |||
Cell proliferation | ||||
In Vitro Model |
SNU-449 cells | Adult hepatocellular carcinoma | Homo sapiens | CVCL_0454 |
SK-HEP-1 cells | Liver and intrahepatic bile duct epithelial neoplasm | Homo sapiens | CVCL_0525 | |
MHCC97-H cells | Adult hepatocellular carcinoma | Homo sapiens | CVCL_4972 | |
SMMC-7721 cells | Endocervical adenocarcinoma | Homo sapiens | CVCL_0534 | |
LM3 cells | Malignant neoplasms | Mus musculus | CVCL_D269 | |
Huh-7 cells | Hepatocellular carcinoma | Homo sapiens | CVCL_0336 | |
PLC/PRF/5 cells | Hepatocellular carcinoma | Homo sapiens | CVCL_0485 | |
L-02 cells | Endocervical adenocarcinoma | Homo sapiens | CVCL_6926 | |
Response regulation | GABARAPL1 was downregulated in hepatocellular carcinoma (HCC) tumor-repopulating cells (TRC; a type of CSLC). Its downregulation decreased the sensitivity of HCC TRC to erastin- or sorafenib-triggered ferroptosis. | |||